Generate Biomedicines Inc.
GENB evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $2.02B
- Lead Asset:
- gb-4362 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for GENB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GENB
Generate Biomedicines Inc. (GENB) is a publicly traded biotechnology company that leverages artificial intelligence to design and develop novel protein-based therapeutics, with a pipeline spanning respiratory, oncology, and cell therapy programs.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.02B
Cash Runway
—
Lead Asset
gb-4362 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials for Generate Biomedicines Inc..
Generate Biomedicines Inc. (GENB) is a publicly traded biotechnology company that leverages artificial intelligence to design and develop novel protein-based therapeutics, with a pipeline spanning respiratory, oncology, and cell therapy programs.
- Cash, cash equivalents, and marketable securities of approximately $457.4 million as of mid-2026 [news · 2026-08-06].
- Phase 3 studies (SOLAIRIA-1 and SOLAIRIA-2) for GB-0895 (anti-TSLP) in severe asthma are recruiting across six global regions [news · 2026-08-06].
- First patient dosed in first-in-human Phase 1 trial of GB-5267, an AI‑engineered, IL‑18 armored CAR T‑cell therapy for ovarian cancer [news · 2026-10-01].
- Phase 1b data for GB-0895 in COPD to be presented at the European Respiratory Society (ERS) Congress 2026 on September 8 [news · 2026-08-06].
- GB-4362 (MMAE neutralizer) is in Phase 1 for advanced urothelial cancer, with 53 competitors listed in the same indication [pipeline].
What works
- Strong cash position of ~$457.4 million provides substantial runway to advance multiple clinical programs without near-term financing pressure [news · 2026-08-06].
- AI‑driven platform has generated a diverse pipeline including respiratory biologics, oncology antibody‑drug conjugates, and next‑generation cell therapies, demonstrating platform versatility [news · 2026-10-01].
- GB-5267, an IL‑18 armored CAR T‑cell therapy, has entered first‑in‑human trials for ovarian cancer, a solid tumor indication where cell therapy has historically been challenging [news · 2026-10-01].
What to weigh
- Net income of -$67.3M for the six months ended June 30, 2026, reflecting significant ongoing R&D investment and no approved product revenue [latest reported financials].
- GB-4362 faces a highly competitive landscape with 53 competitors, including large pharma and established ADCs, in advanced urothelial cancer [pipeline].
- Draft posters for GB-0895 COPD data were inadvertently released early, indicating potential operational or disclosure control risks [news · 2026-08-26].
From the filings
Quoted directly from source documents.
Cash position as of mid-2026
“Approximately $457.4 million in cash, cash equivalents, and m”
News · August 6, 2026
Phase 3 recruitment for GB-0895 in severe asthma
“SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions”
News · August 6, 2026
First patient dosed in GB-5267 CAR T trial
“First patient dosed in first-in-human trial of GB-5267 CAR T-cell therapy for ovarian cancer”
News · October 1, 2026
GB-4362 competitive landscape
“53 competitors: AstraZeneca (Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin, PHASE2); Yuhan Corporation (YH32364, PHASE1/PHASE2); Bayer (BAY2927088, PHASE2); Rahul Aggarwal (Ceralasertib, Olaparib, Durvalumab, PHASE2); Merck Sharp & Dohme LLC (Zilovertamab vedotin, Pembrolizumab, MK-3120, PHASE1/PHASE2)”
Catalyst timeline
- 2023-07-18 · Phase 1 start for GB-0669 — First‑in‑human single ascending dose study in healthy subjects; no update on subsequent phases in provided chunks.
- 2023-12-12 · Phase 1 start for GB-0895 — First‑in‑human single and multiple ascending dose study in mild‑to‑moderate asthma or COPD; Phase 3 now recruiting.
- 2024-11-15 · Phase 2 start for ENV-101 — Multi‑center, randomized, double‑blind, controlled trial evaluating safety and efficacy; no further details in provided chunks.
Risks & what to watch (3)›
Key risks
- No approved products — Company has no marketed products; net loss of $67.3M in first half of 2026 reflects heavy R&D spend [latest reported financials].
- Competitive pressure in oncology — GB-4362 faces 53 competitors in advanced urothelial cancer, including ADCs from AstraZeneca and others [pipeline].
- Operational disclosure risk — Draft posters for GB-0895 COPD data were inadvertently made public before embargo lifted [news · 2026-08-26].
What to watch
- GB-0895 Phase 1b COPD data presentation at ERS Congress 2026 on September 8 [news · 2026-08-06].
- Progress of SOLAIRIA-1 and SOLAIRIA-2 Phase 3 studies for GB-0895 in severe asthma [news · 2026-08-06].
- Initial safety and efficacy data from the GB-5267 first-in-human CAR T trial in ovarian cancer [news · 2026-10-01].
- GB-4362 Phase 1 dose‑escalation results in advanced urothelial cancer [pipeline].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run Generate Biomedicines Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Generate Biomedicines Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.23 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 2.8%
- Days to cover
- 5.7
- Shares short
- 2,078,055
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GENB short interestFrequently asked questions
What is the AI investment thesis for Generate Biomedicines Inc.?
Generate Biomedicines Inc. (GENB) is a publicly traded biotechnology company that leverages artificial intelligence to design and develop novel protein-based therapeutics, with a pipeline spanning respiratory, oncology, and cell therapy programs.
What is Generate Biomedicines Inc.'s lead drug candidate?
Generate Biomedicines Inc.'s most advanced tracked candidate is gb-4362 (Phase 1) for Advanced Urothelial Cancer.
Who is the CEO of Generate Biomedicines Inc.?
Mr. Michael T. Nally M.B.A. is the chief executive officer of Generate Biomedicines Inc. (GENB).
Where is Generate Biomedicines Inc. headquartered?
Generate Biomedicines Inc. (GENB) is headquartered in Somerville, MA, United States.
What therapeutic areas does Generate Biomedicines Inc. focus on?
Generate Biomedicines Inc. develops therapies across Oncology, Immunology, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.